Research onlyGrowth hormoneSubcutaneousEvidence 3/5

CJC-1295

Also known as: DAC:GRF

Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.

CJC-1295 product image
Drug class
GHRH analog (with or without DAC)
Primary targets
GHRH receptor
Dose reference
1–2 mg weekly (DAC, research)
Half-life
~6–8 days (DAC)
Developer / origin
ConjuChem (original)
Reference year
2005
Evidence score
3/5 - Limited human pharmacology
Evidence 3/5

Limited human pharmacology

CJC-1295 has human pharmacology data showing prolonged GH/IGF-1 stimulation, but it is not approved and lacks long-term outcome evidence.

Limited human pharmacology or small clinical evidence.

Evidence basis

  • Human GH/IGF-1 pharmacology
  • Long-acting GHRH analog data
  • No approved indication

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

CJC-1295 guides

Read the matching guide or adjacent research pages for more context.

CJC-1295 calculator shortcuts

Open peptide calculators with editable CJC-1295 example values already filled in.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Ipamorelin

NNC 26-0161

3/5
Growth hormoneResearch only

Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.

5/5
Growth hormoneApproved

Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

IGF-1 LR3

Long R3 IGF-1

2/5
Growth hormoneResearch only

A modified IGF-1 that binds IGF binding proteins far more weakly than native IGF-1, leaving it free to act as a potent, long-acting agonist at the IGF-1 receptor.

IGF-1 DES

DES(1-3) IGF-1

2/5
Growth hormoneResearch only

Removal of the N-terminal tripeptide sharply lowers IGF-binding-protein affinity while preserving IGF-1 receptor binding, leaving more free peptide to activate IGF-1R.

Category hub

Open the category page for the full comparison table and FAQ.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.